Opinion

Video

Private Label Biosimilars

Author(s):

Sophia Humphreys, PharmD, MHA, BCBBSChad Cannon, PharmD, BCCCP

The expert panel discusses the greater potential for private label biosimilars.

Video content above is prompted by the following questions:

  • Some healthcare companies are investigating the potential for private label biosimilars, including products like adalimumab. What is the value of offering a private label biosimilar to patients? What are some of the challenges that may arise?
Related Videos
A panel of 4 experts on CLL
A panel of 4 experts on CLL
A panel of 4 experts on lung cancer
A panel of 4 experts on breast cancer
A panel of 4 experts on lung cancer
A panel of 4 experts on CLL
A panel of 4 experts on CLL
Related Content
Rows of identical clear vials | Image credit: nordroden - stock.adobe.com
September 4th 2024

Drug Survival of Biosimilars, Originator TNF Inhibitors Similar

Laura Joszt, MA
The rates of discontinuation due to inefficacy or adverse events for biosimilars and originators of etanercept and adalimumab were similar, according to an analysis of a prospective registry.
managed care cast banner
August 17th 2022

How Health Care Institutions Can Leverage Biosimilars to Generate Savings

Skylar Jeremias
On this episode of Managed Care Cast, Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and the Winship Cancer Institute, explains the evolution of biosimilar pharmacoeconomics and the different strategies that health care institutions can implement to reap the benefits of biosimilar savings.
Interest rates control inflation | Image Credit: Thongdee - stock.adobe.com
August 16th 2024

Biosimilar Uptake Lags in US Despite Potential Cost Savings

Cameron Santoro
Delayed biosimilar uptake in the US is driven by payer, provider, and patient barriers, but targeted interventions can help boost utilization and savings.
Managed Care Cast
June 14th 2022

Biosimilar Whisky? This Expert Says It’s Doable, No Aging Required

On this episode of Managed Care Cast, we’re highlighting a hobby from a biosimilar expert who says he can make whisky more accessible and affordable through—you guessed it—his own biosimilar whisky.
eye and tech | Image credit: eevl - stock.adobe.com
August 13th 2024

FDA Approves Biosimilar Enzeevu for Eye Conditions

Skylar Jeremias
The FDA approved Sandoz’ Enzeevu, the fourth aflibercept biosimilar to be approved for Americans with age-related macular degeneration and other retinal eye diseases.
Close of up of an older woman's eye | Image credit: Syda Productions - stock.adobe.com
May 20th 2024

First Aflibercept Biosimilars Approved in US

Skylar Jeremias
The FDA approved the first 2 biosimilars referencing aflibercept (Eylea). However, patent litigation has left it unclear when the biosimilars will come to market.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
CH LogoCenter for Biosimilars Logo